Highlights
- A large-scale multi-cohort study identified 23 plasma proteins associated with incident venous thromboembolism (VTE), 15 of which were previously unknown to the disease’s pathophysiology.
- Key novel markers include TIMD4, TIMP4, Cystatin-C, and Transgelin, representing biological pathways such as extracellular matrix regulation, immunity, and vascular senescence.
- Mendelian randomization (MR) provided significant evidence for a causal role of TIMD4 and suggestive evidence for TIMP4 and Cystatin-C in VTE risk.
- The integration of aptamer-based (SomaScan) and antibody-based (Olink) proteomic platforms enhances the robustness of these findings across diverse populations.
Background
Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), remains a major cause of global cardiovascular morbidity and mortality. Despite decades of research into the Virchow’s Triad—stasis, endothelial injury, and hypercoagulability—the underlying etiology for many incident VTE cases remains elusive. Traditional risk factors and established biomarkers, such as D-dimer and factor VIII, primarily reflect the activation of the coagulation cascade rather than the upstream biological drivers of thrombus formation.
There is a critical unmet need for novel biomarkers that can improve the precision of VTE risk stratification and provide mechanistic insights into its complex pathophysiology. Recent advancements in high-throughput proteomics offer an unprecedented opportunity to scan thousands of circulating proteins simultaneously, facilitating the discovery of non-traditional pathways involved in thromboinflammation and vascular health. This review analyzes the recent landmark study by Tang et al. (2026), which utilizes these technologies to redefine the VTE proteomic landscape.
Key Content
Study Design and Methodological Rigor
The investigation employed a sophisticated multi-stage discovery and replication design. The discovery phase utilized four longitudinal cohorts: the Atherosclerosis Risk in Communities (ARIC) study, the Cardiovascular Health Study (CHS), the Multi-Ethnic Study of Atherosclerosis (MESA), and the Trøndelag Health (HUNT) study. This meta-analysis included over 20,000 participants and 1,371 incident noncancer VTE events, with follow-up periods spanning up to 29 years.
The primary analytical tool was the SomaScan platform, which uses aptamer-based technology to measure approximately 5,000 to 7,000 proteins. To ensure the reliability of the findings, the researchers conducted external replication using the UK Biobank (UKB) study, which leveraged the Olink proteomics platform (proximity extension assay). This cross-platform validation is significant, as it minimizes the likelihood of platform-specific artifacts and reinforces the biological validity of the identified
**Finalizing the Content**
I am now meticulously crafting the JSON content, focusing on detailed explanations of the key proteins and pathways. I am incorporating the clinical context of current VTE risk assessment and the potential for these novel markers to refine long-term prediction. The review will be comprehensive, and I am targeting the higher end of the word count. I’m also double-checking the reference formatting and refining the thumbnail prompt.
markers.
The Emerging VTE Proteome: Novel Targets
The meta-analysis identified 23 proteins associated with incident VTE at a false discovery rate (FDR)-adjusted P < 0.05. Crucially, 15 of these proteins had not been previously linked to VTE in literature. Among the most notable findings were:
- TIMP4 (Metalloproteinase Inhibitor 4): A key regulator of the extracellular matrix (ECM). Its involvement suggests that structural changes in the venous wall or valves may play a more central role in VTE than previously recognized.
- TIMD4 (T-cell Immunoglobulin and Mucin Domain-containing Protein 4): Involved in immunity and phagocytosis of apoptotic cells. This suggests a link between immune clearance mechanisms and the initiation of thrombosis.
- CST3 (Cystatin-C): Traditionally a marker of renal function, its consistent association across cohorts indicates that it may reflect systemic inflammation or vascular aging relevant to VTE.
- Transgelin and SVEP1: Proteins associated with vascular smooth muscle cell function and cell adhesion, highlighting the importance of the vessel wall microenvironment.
Causality via Mendelian Randomization
A standout feature of this research was the use of Mendelian randomization (MR) to differentiate between causal proteins and simple biomarkers of disease. MR analysis of the 15 novel proteins provided significant evidence that TIMD4 may play a causal role in VTE. Interestingly, the direction of association in the MR analysis for TIMP4 and TIMD4 was opposite to that found in the longitudinal proteomics analysis. Such divergence often suggests compensatory biological mechanisms or complex feedback loops; for instance, a protein might increase in the plasma as a protective response to a developing pathology, even if its genetically predicted levels suggest an inverse risk relationship.
Biological Pathways Beyond Coagulation
The identified proteins converge on several themes that expand the traditional understanding of VTE:
- Extracellular Matrix (ECM) Remodeling: Proteases and their inhibitors (like TIMP4) regulate the structural integrity of the vasculature. Disruptions in this balance may predispose individuals to venous stasis or endothelial dysfunction.
- Immune-Vascular Interactions: The presence of proteins like TIMD4 underscores the concept of ‘thromboinflammation,’ where the immune system and the coagulation cascade are inextricably linked.
- Vascular Senescence: Several markers are associated with aging at the cellular level, suggesting that VTE risk is tied to the biological ‘age’ of the veins rather than just chronological age.
Expert Commentary
This study represents a significant leap forward in cardiovascular proteomics. From a clinical perspective, the transition from discovery to external replication in the UK Biobank is particularly compelling. The fact that 11 of the 16 available proteins replicated across different technologies (SomaScan vs. Olink) and different populations provides high confidence in these markers.
However, several caveats remain. First, while these proteins improve risk prediction, their immediate integration into clinical practice requires the development of standardized, cost-effective assays. Second, the discrepancy in the directionality of MR results for TIMD4 and TIMP4 warrants further mechanistic investigation in preclinical models. It is possible that circulating levels of these proteins are modulated by subclinical disease long before a VTE event occurs.
Furthermore, the focus on noncancer VTE is a strength for identifying baseline biological drivers but means these results may not be fully generalizable to cancer-associated thrombosis, which is driven by distinct mucin-mediated and tissue factor-rich pathways. Future research should investigate whether these 23 proteins can improve the performance of clinical risk scores like the Caprini or Padua scores.
Conclusion
The identification of novel plasma proteomic markers such as TIMD4, TIMP4, and CST3 provides a transformative view of venous thromboembolism as a disease not just of blood clotting, but of vascular health, immunity, and matrix regulation. These findings offer potential new targets for therapeutic intervention and more granular tools for risk stratification. As we move toward a precision medicine approach in cardiovascular care, the integration of these proteomic signatures into routine clinical assessment could significantly reduce the global burden of VTE.
References
- Tang W, Li A, Austin TR, et al. Novel Plasma Proteomic Markers and Risk of Venous Thromboembolism. Circulation. 2026 Mar 17;153(11):810-825. doi: 10.1161/CIRCULATIONAHA.125.074493. PMID: 41693575.
- Cushman M. Epidemiology and risk factors for venous thromboembolism. Hematology Am Soc Hematol Educ Program. 2007:450-457. doi: 10.1182/asheducation-2007.1.450.
- Pankratz N, et al. Genome-wide association study for incident venous thromboembolism in the African American and European American participants of the ARIC study. J Thromb Haemost. 2011;9(6):1105-1127.